Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EULAST trial of long-acting injectable versus oral antipsychotics in schizophrenia
NL-OMON44336Phase 4Active, not recruiting
- Sponsor
- European Group for Research in Schizophrenia
- Start
- Mar 2016
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole, paliperidone palmitate and paliperidone in schizophrenia, sponsored by European Group for Research in Schizophrenia. Primary endpoint: All-cause discontinuation. Started Mar 2016; status: active, not recruiting.
02
Drugs
aripiprazolepaliperidone palmitatepaliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON44336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44336.